Zaccardi et al. conducted a meta-analysis of 38 randomized controlled trials involving 23,997 participants to evaluate the efficacy and safety of SGLT2 inhibitors in adults with T2DM (Zaccardi et al., 2016). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.